Pfizer has discontinued the final clinical study stemming from its 2021 acquisition of Trillium Therapeutics, funneling cash primarily toward a host of other cancer and

Scientists trying to understand why cancer immunotherapy works so well for some patients and not others have found a potential answer in one cancer survivor’s

Johnson & Johnson will move a treatment for inflammatory bowel disease into Phase 3 studies despite the therapy’s failure in two mid-stage trials. The company

Cytokinetics’ Myqorzo has succeeded where BMS’s first-to-market Camzyos failed, with a positive trial in non-obstructive hypertrophic cardiomyopathy.

Madrigal Pharmaceuticals has made its fourth MASH deal in 10 months, further signaling its ambitions to be not just the first drugmaker for the fatty